Factive
Executive Summary
GlaxoSmithKline is hoping for approval of quinolone antibiotic Factive (gemifloxacin) in time for the 2002 flu season, VP-New Product Development James Palmer tells Goldman Sachs conference. FDA issued a "not-approvable" letter for the drug in December (1"The Pink Sheet" Dec. 18, 2000, In Brief)